AdvantiGen Biosciences, a start-up immunotherapy company, utilizes our patented technologies to create monoclonal antibodies (drugs) for the treatment of cancer and other diseases. We’re developing a new drug to a previously unknown cancer target. This new Immune Checkpoint Inhibitor drug has the potential to reach Billions in annual sales. Our team has decades of experience in drug discovery & development and our technology is up to 100x more efficient than other approaches.